Introduction: Up to 73% of patients with neuroendocrine neoplasms (NEN) present with distant metastases at diagnosis. Advanced stage negatively correlates with prognosis. Bone metastases (BM) are usually reported in less than 10% of patients. Improved imaging results in more frequent detection but information in general is very limited.
Aim(s): Presentation of a single-center experience on frequency, clinical and therapeutic relevance of BM.
Materials and methods: All patients treated in the ENETs center in Marburg, Germany, between 2000 and June 2015 listed in our NEN-database were evaluated for inclusion. Out of 709 patients 414 had distant metastases (58.4 %) including 109 with BM (15.4%). 84 patients qualified for inclusion in our study.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MD Michael Scharf
To read results and conclusion, please login ...
Further abstracts you may be interested in
Introduction: Brain metastases are rarely reported in patients with neuroendocrine carcinoma (NEC) of non-lung origin and neuroendocrine tumors (NETs) of the gastroenteropancreatic or bronchopulmonary system. Symptomatic brain metastases are associated with dismal prognosis, so early detection and treatment could be advisable.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr. med. Anja Rinke
Introduction: Pancreatic metastases are rare, accounting for 1 to 2% of pancreatic tumours. Data on pancreatic metastases of intestinal NETs are lacking.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Anja Rinke
Introduction: FDOPA-PET has high sensitivity to detect siNET and associated metastases.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr Louis de Mestier
Introduction: Hepatic metastases significantly affect the overall prognosis and quality of life in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NET). Radiofrequency ablation (RFA) is one of the important local ablative strategies for hepatic metastases. Peptide receptor radionuclide therapy (PRRNT) is a well-established therapeutic modality for metastatic NET.
Conference: 9th Annual ENETS Conference (2012)
Presenting Author: Prof. Dr. Richard P Baum
Introduction: Bronchopulmonary neuroendocrine tumors (BP-NETs) comprise 20% of all lung cancers. Typical low grade carcinoid tumors (TC) represent the majority of BP-carcinoids. Intermediate grade atypical carcinoid tumors (AC) are less often encountered but more aggressive. Although metastatic dissemination to mediastinal lymph nodes, liver, skeleton and central nervous system (CNS) is common, involvement of the endocrine glands has rarely been reported.
Conference: 7th Annual ENETS Conference (2010)
Presenting Author: Dr Vasiliki Daraki